Adaptive clinical trial

From Wikipedia, the free encyclopedia
Jump to: navigation, search

An adaptive clinical trial is a clinical trial that evaluates patients' reactions to a drug beginning early in a clinical trial and modifies the trial in accord with those findings. The adaptation process continues throughout the trial. Modifications may include dosage, sample size, drug undergoing trial, patient selection criteria and "cocktail" mix.[1] In some cases, trials have become an ongoing process that regularly adds and drops therapies and patient groups as more information is gained.[2] The aim is to more quickly identify drugs that have a therapeutic effect and to zero in on patient populations for whom the drug is appropriate.[3] A key modification is to adjust dosing levels.[2] Traditionally, non-adverse patient reactions are not considered until a trial is completed.[3][4]

History[edit]

In 2004, a Strategic Path Initiative was introduced by the United States’ Food and Drug Administration (FDA) to modify the way drugs travel from lab to market. This initiative aimed at dealing with the high attrition levels observed in the clinical phase. It also attempted to offer flexibility to investigators to find the optimal clinical benefit without affecting the study's validity. Adaptive clinical trials initially came under this regime.[2]

The FDA issued draft guidance on adaptive trial design in 2010.[3] In 2012, the President's Council of Advisors on Science and Technology (PCAST) recommended that FDA "run pilot projects to explore adaptive approval mechanisms to generate evidence across the life­cycle of a drug from the pre­market through the post­market phase." While not specifically related to clinical trials, the Council also recommended that FDA "make full use of accelerated approval for all drugs meeting the statutory standard of addressing an unmet need for a serious or life­threatening disease, and demonstrating an impact on a clinical endpoint other than survival or irreversible morbidity, or on a surrogate endpoint, likely to predict clinical benefit."[5]

In the 2007–2009 period, the Department of Biostatistics at the M. D. Anderson Cancer Center was running 89 Bayesian adaptive trials, 36% of the total designed by the faculty.[6]

Bayesian designs[edit]

According to FDA guidelines, an adaptive Bayesian clinical trial can involve:[7]

  • Interim looks to stop or to adjust patient accrual
  • Interim looks to assess stopping the trial early either for success, futility or harm
  • Reversing the hypothesis of non-inferiority to superiority or vice-versa
  • Dropping arms or doses or adjusting doses
  • Modification of the randomization rate to increase the probability that a patient is allocated to the most appropriate arm

Abandoned drugs[edit]

Research groups are partnering with companies to take over research on abandoned compounds. The concept is that the value of some drugs was obscured by conventional trial protocols. Companies have begun sharing results on failed drugs, with the aim of figuring out whether the too-small number of patients who benefited from the drug can be characterized, leading to a targeted therapy for such patients.[3]

Britain's Cancer Research UK plans to reinvigorate research on promising chemical compounds that companies abandon. At the end of a trial, companies can pay a fee to examine the data and resume work on the compound. Otherwise, the group can team with another company. Currently, nine compounds are under development through the program.[3]

About 30% of experimental chemical compounds fail in early-stage testing, and even more in later stages. Because of this, pharmaceutical companies may stop work and instead devote resources elsewhere.[3]

Adaptive licensing[edit]

"Adaptive licensing" is a new approval system that would allow new drugs to be approved conditionally and their use restricted to patients who meet specific criteria. Under the current system, once a drug is licensed, any physician can prescribe it for any patient. Under the new approach companies would continue to assess effectiveness and safety using data from approved patients.[3]

Sanofi SA's diet pill Acomplia was removed from the European market in 2009 because of concerns over safety. The medication had appeared to work without problems in clinical trials. A later analysis found that Acomplia failed for multiple reasons, including that patients failed to follow the treatment protocol. Doctors failed to follow patients closely and were prescribing the drug for unapproved conditions. Adaptive licensing would have avoided such problems.[3]

PCAST also recommended what it called a "Special Medical Use" license for drugs that had been shown to be safe and effective in a specific group of patients.[5]

Logistics[edit]

The logistics of managing traditional, fixed format clinical trials are quite complex. Adapting the design as results arrive adds to the complexity of design, monitoring, drug supply, data capture and randomization.[2] However, according to PCAST "One approach is to focus studies on specific subsets of patients most likely to benefit, identified based on validated biomarkers. In some cases, using appropriate biomarkers can make it possible to dramatically decrease the sample size required to achieve statistical significance—for example, from 1500 to 50 patients."[8]

Disease targets[edit]

Breast cancer[edit]

An adaptive trial design enabled two experimental breast cancer drugs to deliver promising results after just six months of testing, far shorter usual. Researchers assessed the results while the trial was in process and found that cancer had been eradicated in more than half of one group of patients. The trial, known as I-Spy 2, tested 12 experimental drugs.[3]

I-SPY 1[edit]

For its predecessor I-SPY 1, 10 cancer centers and the National Cancer Institute (NCI SPORE program and the NCI Cooperative groups) collaborated to identify response indicators that would best predict survival for women with high-risk breast cancer. During 2002–2006, the study monitored 237 patients undergoing neoadjuvant therapy before surgery. Iterative MRI and tissue samples monitored the biology of patients to chemotherapy given in a neoadjuvant setting, or pre­surgical setting. Evaluating chemotherapy's direct impact on tumor tissue took much less time than monitoring outcomes in thousands of patients over long time periods. The approach helped to standardize the imaging and tumor sampling processes, and led to miniaturized assays. Key findings included that tumor response was a good predictor of patient survival, and that tumor shrinkage during treatment was a good predictor of long-term outcome. Importantly, the vast majority of tumors identified as high risk by molecular signature. However, heterogeneity within this group of women and measuring response within tumor subtypes was more informative than viewing the group as a whole. Within genetic signatures, level of response to treatment appears to be a reasonable predictor of outcome. Additionally, is shared database has furthered the understanding of drug response and generated new targets and agents for subsequent testing.[9]

I-SPY 2[edit]

I-SPY 2 is an adaptive clinical trial of multiple Phase 2 treatment regimens combined with standard chemotherapy. I-SPY 2 linked 19 academic cancer centers, two community centers, the FDA, the NCI, pharmaceutical and biotech companies, patient advocates and philanthropic partners. The trial is sponsored by the Biomarker Consortium of the Foundation for the NIH (FNIH), and is co-managed by the FNIH and QuantumLeap Healthcare Collaborative. I-SPY 2 was designed to explore the hypothesis that different combinations of cancer therapies have varying degrees of success for different patients. Conventional clinical trials that evaluate post-surgical tumor response require a separate trial with long intervals and large populations to test each combination. Instead, I-SPY 2 is organized as a continuous process. It efficiently evaluates multiple therapy regimes by relying on the predictors developed in I-SPY 1 that help quickly determine whether patients with a particular genetic signature will respond to a given treatment regime. The trial is adaptive in that the investigators learn as they go, and do not continue treatments that appear to be ineffective. All patients are categorized based on tissue and imaging markers collected early and iteratively (a patient's markers may change over time) throughout the trial, so that early insights can guide treatments for later patients. Treatments that show positive effects for a patient group can be ushered to confirmatory clinical trials, while those that do not can be rapidly sidelined. Importantly, confirmatory trials can serve as a pathway for FDA Accelerated Approval. I-SPY 2 can simultaneously evaluate candidates developed by multiple companies, escalating or eliminating drugs based on immediate results. Using a single standard arm for comparison for all candidates in the trial saves significant costs over individual Phase 3 trials. All data are shared across the industry.[9]

Alzheimer's[edit]

Researchers plan to use an adaptive trial design to help speed development of Alzheimer's disease treatments, with a budget of 53 million euros. The first trial under the initiative was expected to begin in 2015 and to involve about a dozen companies. One participant is Johnson & Johnson which stated that the benefit is that multiple drugs can be tested and winners and losers identified sooner than in a standard trial.[3]

A project spearheaded by the Coalition Against Major Diseases shares negative outcomes to help better understand how the disease progresses to understand whether a clinical trial failed for a logistical reason, such as too few patients, or whether the drug has no effect. CAMD developed a simulation tool to help figure out how best to design future trials.[3]

Risks[edit]

Shorter trials may not reveal longer term risks, such as a cancer's return.[3]

See also[edit]

References[edit]

Sources[edit]

External links[edit]